Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: J Allergy Clin Immunol. 2018 Feb 10;142(6):1773–1780.e9. doi: 10.1016/j.jaci.2017.12.1004

Figure 4.

Figure 4

Refractory asthma as indicated by systemic corticosteroid treatment (CS) compared to subjects on other non-systemic therapies is starkly different for all CT biomarkers where * indicates significance at the p<0.05 level. A) Mean and 95% CI show significantly greater WT% for systemic CS treatment at generations 4 and 5, the subsegmental airways. B) Mean and 95% CI for Delta Lumen is reduced in subjects treated with systemic corticosteroids (CS) at generations 3–5. C) Mean and 95% CI for LAA in percent of expiratory lung volume is greater in subjects treated with systemic corticosteroids (CS).